The DOI matches its Crossref record; 25 of the 27 references it cites were found in a registry or an index.
Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa
Abstract
OBJECTIVE: To determine the burden and impact of immune reconstitution disease (IRD) associated with tuberculosis (TB) among patients initiating antiretroviral treatment (ART) in sub-Saharan Africa. DESIGN: Retrospective analysis of a study cohort enrolled over 3 years within a community-based ART service in South Africa. METHODS: Patients receiving treatment for TB at the time ART was initiated (n = 160) were studied. Cases of TB-associated IRD during the first 4 months of ART were ascertained. RESULTS: The median baseline CD4 cell count was 68 cells/microl [interquartile range (IQR), 29-133 cells/microl) and ART was initiated after a median of 105 days (IQR, 61-164 days) from TB diagnosis. Although IRD was diagnosed in just 12% (n = 19) of patients overall, IRD developed in 32% (n = 12) of those who started ART within 2 months of TB diagnosis. Pulmonary involvement was observed in 84% (n = 16) and intra-abdominal manifestations were also common (37%). Overall, 4% (n = 7) of the cohort required secondary level health-care for IRD and two (1%) patients died. In multivariate analysis, risk of IRD was strongly associated with early ART initiation and low baseline CD4 cell count. Of patients with CD4 counts < 50 cells/microl, the proportions who developed IRD following initiation of ART within 0-30, 31-60, 61-90, 91-120 and > 120 days of TB diagnosis were 100%, 33%, 14%, 7% and 0%, respectively. CONCLUSIONS: The risk of TB-associated IRD in this setting is very high for those with low baseline CD4 cell counts initiating ART early in the course of antituberculosis treatment. However, most cases were self-limiting; overall secondary health-care utilization and mortality risk from IRD were low.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, HIV-positive patients with apparent sole pulmonary tuberculosis may develop peripheral or central lymphadenitis as the manifestation of IRIS [58].”
From Current diagnosis and management of peripheral tuberculous lymphadenitis. (2011) · cites this paper as [58]
Citations
Cites
(1990) · Choice Reviews Online · doi:10.5860/choice.27-3338 · Cited by 35,305
The Growing Burden of Tuberculosis: Global Trends and Interactions With the HIV Epidemic
Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C., & Dye, C. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1009 · Cited by 2,553 · cited 1×
“A majority of the global burden of HIV-associated tuberculosis (TB) lies in sub-Saharan Africa [1] and rates in southern Africa have reached almost unprecedented”
BackgroundTuberculosis in Patients with Human Immunodeficiency Virus Infection
Havlir, D. V., & Barnes, P. F. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902043400507 · Cited by 1,461 · cited 1×
“Moreover, the risks associated with TB-IRD are important variables in the debate over the optimal time for ART initiation in patients with TB [7,8,10].”
BackgroundShelburne, S. A., Visnegarwala, F., Darcourt, J., Graviss, E. A., Giordano, T. P., White, A. C., & Hamill, R. J. (2005) · AIDS · doi:10.1097/01.aids.0000161769.06158.8a · Cited by 632 · cited 3×
“In common with most previous studies [9,19,20,22,23], diagnoses of IRD were made retrospectively but were nevertheless based on systematically collected prospective data.”
BackgroundParadoxical Worsening of Tuberculosis Following Antiretroviral Therapy in Patients with AIDS
NARITA, M., ASHKIN, D., HOLLENDER, E. S., & PITCHENIK, A. E. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.158.1.9712001 · Cited by 608 · cited 2×
“patients attending referral hospitals [9,20,21,23].”
ResultLawn, S. D., Bekker, L.-G., & Miller, R. F. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70140-7 · Cited by 545 · cited 7×
“Moreover, the risks associated with TB-IRD are important variables in the debate over the optimal time for ART initiation in patients with TB [7,8,10].”
BackgroundMethodInfluentialSelf-citationParadoxical reactions during tuberculosis treatment in patients with and without HIV co-infection
Breen, R. A. M. (2004) · Thorax · doi:10.1136/thx.2003.019224 · Cited by 367 · cited 4×
“In common with most previous studies [9,19,20,22,23], diagnoses of IRD were made retrospectively but were nevertheless based on systematically collected prospective data.”
BackgroundInfluentialLawn, S. D., Myer, L., Bekker, L.-G., & Wood, R. (2006) · AIDS · doi:10.1097/01.aids.0000238406.93249.cd · Cited by 363
Self-citationLawn, S. D., Myer, L., Orrell, C., Bekker, L.-G., & Wood, R. (2005) · AIDS · doi:10.1097/01.aids.0000194802.89540.e1 · Cited by 359 · cited 3×
“reported that cryptococcal IRD is a far more common cause of death in this service [12,15].”
BackgroundMethodResultSelf-citationTreatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy
Dean, G. L., Edwards, S. G., Ives, N. J., Matthews, G., Fox, E. F., Navaratne, L., Fisher, M., Taylor, G. P., Miller, R., Taylor, C. B., et al. (2002) · AIDS · doi:10.1097/00002030-200201040-00010 · Cited by 354
Cited by
WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update
Falzon, D., Jaramillo, E., Schünemann, H. J., Arentz, M., Bauer, M., Bayona, J., Blanc, L., Caminero, J. A., Daley, C. L., Duncombe, C., et al. (2011) · European Respiratory Journal · doi:10.1183/09031936.00073611 · Cited by 1,100
Müller, M., Wandel, S., Colebunders, R., Attia, S., Furrer, H., & Egger, M. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70026-8 · Cited by 755
Meintjes, G., Lawn, S. D., Scano, F., Maartens, G., French, M. A., Worodria, W., Elliott, J. H., Murdoch, D., Wilkinson, R. J., Seyler, C., et al. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70184-1 · Cited by 745
“Median 32 days (IQR 14–115 days) Extrapulmonary tuberculosis Lawn et al (2007)10 South Africa 160 19 (12”
Self-citationThwaites, G., Fisher, M., Hemingway, C., Scott, G., Solomon, T., & Innes, J. (2009) · Journal of Infection · doi:10.1016/j.jinf.2009.06.011 · Cited by 666
Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa
Lawn, S. D., Harries, A. D., Anglaret, X., Myer, L., & Wood, R. (2008) · AIDS · doi:10.1097/qad.0b013e32830007cd · Cited by 639
“Although most cases appear to be self-limiting, a minority are severe, and deaths have been reported from cohorts in South Africa and Thailand [57,58].”
BackgroundSelf-citationTiming of Antiretroviral Therapy after Diagnosis of Cryptococcal Meningitis
Boulware, D. R., Meya, D. B., Muzoora, C., Rolfes, M. A., Huppler Hullsiek, K., Musubire, A., Taseera, K., Nabeta, H. W., Schutz, C., Williams, D. A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312884 · Cited by 497
Integration of Antiretroviral Therapy with Tuberculosis Treatment
Abdool Karim, S. S., Naidoo, K., Grobler, A., Padayatchi, N., Baxter, C., Gray, A. L., Gengiah, T., Gengiah, S., Naidoo, A., Jithoo, N., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014181 · Cited by 487
Meintjes, G., Wilkinson, R. J., Morroni, C., Pepper, D. J., Rebe, K., Rangaka, M. X., Oni, T., & Maartens, G. (2010) · AIDS · doi:10.1097/qad.0b013e32833dfc68 · Cited by 405
“Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) is increasingly recognized as an early complication of ART [2,3].”
BackgroundImmune Reconstitution Inflammatory Syndrome: A Reappraisal
French, M. A. (2009) · Clinical Infectious Diseases · doi:10.1086/595006 · Cited by 323
“stantial problem, but mortality is uncommon, with death occurring in ∼1% of patients [11, 44].”
BackgroundPorcel, J. M. (2009) · Lung · doi:10.1007/s00408-009-9165-3 · Cited by 303
“One-third of patients with HIV receiving treatment for TB at the time of antiretroviral treatment develop a clinical deterioration due to an immune reconstitution inflammatory syndrome [50].”
Haddow, L. J., Colebunders, R., Meintjes, G., Lawn, S. D., Elliott, J. H., Manabe, Y. C., Bohjanen, P. R., Sungkanuparph, S., Easterbrook, P. J., French, M. A., et al. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70170-5 · Cited by 302
Self-citationLawn, S. D., Kerkhoff, A. D., Vogt, M., & Wood, R. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70251-1 · Cited by 300
Self-citationCurrent diagnosis and management of peripheral tuberculous lymphadenitis.
Fontanilla, J.-M., Barnes, A., & von Reyn, C. F. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir454 · Cited by 299
“Thus, worsening of tuberculous lymphadenitis in patients with HIV infection and newly initiated ART may reflect the sum of the expected rate of PUR among HIV-negative persons plus an additional contribution from IRIS.”
BackgroundInfluentialLawn, S. D., Brooks, S. V., Kranzer, K., Nicol, M. P., Whitelaw, A., Vogt, M., Bekker, L.-G., & Wood, R. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1001067 · Cited by 278
“Several studies reporting the burden, diagnosis, and complications of TB in this cohort have previously been published [3,5,15,16,30,31].”
BackgroundSelf-citationImmune Reconstitution Inflammatory Syndrome: Risk Factors and Treatment Implications
Manabe, Y. C., Campbell, J. D., Sydnor, E., & Moore, R. D. (2007) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181594c8c · Cited by 206
“Several studies have shown that lower CD4 T-cell counts at the time of HAART initiation increase the risk of developing IRIS.(7,8,15,18) There is little consensus among the studies on other risk factors for IRIS and optimal treatment modalities.”
BackgroundResultPrednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS
Meintjes, G., Stek, C., Blumenthal, L., Thienemann, F., Schutz, C., Buyze, J., Ravinetto, R., van Loen, H., Nair, A., Jackson, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800762 · Cited by 199
Basu, S., Andrews, J. R., Poolman, E. M., Gandhi, N. R., Shah, N. S., Moll, A., Moodley, P., Galvani, A. P., & Friedland, G. H. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61636-5 · Cited by 201
Immune Reconstitution and “Unmasking” of Tuberculosis during Antiretroviral Therapy
Lawn, S. D., Wilkinson, R. J., Lipman, M. C. I., & Wood, R. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200709-1311pp · Cited by 202
“Correspondence and requests for reprints should be addressed to Stephen D. Lawn, M.D., Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory 7925, Cape Town, South Africa.”
ResultInfluentialSelf-citationEpidemiology of HIV-associated tuberculosis
Lawn, S. D., & Churchyard, G. (2009) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e32832c7d61 · Cited by 192
Self-citationLawn, S. D., Edwards, D. J., Kranzer, K., Vogt, M., Bekker, L.-G., & Wood, R. (2009) · AIDS · doi:10.1097/qad.0b013e32832e05c8 · Cited by 191
“diagnosed during routine clinical practice in this service has been previously reported [1,20].”
BackgroundSelf-citationDhasmana, D. J., Dheda, K., Ravn, P., Wilkinson, R. J., & Meintjes, G. (2008) · Drugs · doi:10.2165/00003495-200868020-00004 · Cited by 176
Immune reconstitution inflammatory syndrome: the trouble with immunity when you had none
Barber, D. L., Andrade, B. B., Sereti, I., & Sher, A. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2712 · Cited by 169
Integrating Cryptococcal Antigen Screening and Pre-Emptive Treatment into Routine HIV Care
Rajasingham, R., Meya, D. B., & Boulware, D. R. (2012) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31824c837e · Cited by 159
“In Cape Town, South Africa, the CM-related mortality exceeded that of paradoxical TB-immune reconstitution inflammatory syndrome (IRIS) in a HIV/TB cohort.(21) Thus, screening persons for cryptococcal antigenemia before initiating ART can identify those at highest risk for mortality due to cryptococcosis.”
BackgroundHypercytokinaemia accompanies HIV–tuberculosis immune reconstitution inflammatory syndrome
Tadokera, R., Meintjes, G., Skolimowska, K. H., Wilkinson, K. A., Matthews, K., Seldon, R., Chegou, N. N., Maartens, G., Rangaka, M. X., Rebe, K. B., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00091010 · Cited by 143
“Mortality is difficult to estimate as most series are reported from centres experienced in supportive management: but can be as high as 10-13% [12, 23].”
BackgroundDiagnosis & treatment of tuberculosis in HIV co-infected patients
Swaminathan, S., Padmapriyadarsini, C., & Narendran, G. (2011) · The Indian Journal of Medical Research · doi:10.4103/0971-5916.92630 · Cited by 192
Meintjes, G., Wilkinson, K. A., Rangaka, M. X., Skolimowska, K. H., van Veen, K., Abrahams, M., Seldon, R., Pepper, D. J., Rebe, K. B., Mouton, P., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200806-858oc · Cited by 140
“Initially reported from specialized centers (11, 12), TB–IRIS is now a frequent diagnosis in areas of the world where tuberculosis and HIV frequently coexist (13, 14).”
BackgroundChanging mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa
Lawn, S. D., Little, F., Bekker, L., Kaplan, R., Campbel, E., Orrell, C., & Wood, R. (2009) · AIDS · doi:10.1097/qad.0b013e328321823f · Cited by 134
Self-citationAchenbach, C. J., Harrington, R. D., Dhanireddy, S., Crane, H. M., Casper, C., & Kitahata, M. M. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir802 · Cited by 134
“We found a cumulative incidence of paradoxical IRIS within the first year of ART of 11% (95% CI, 7%–16%), similar to that reported in prospective studies [11, 13, 14, 17, 18].”
ResultFrequency, severity and duration of immune reconstitution events in HIV-related tuberculosis.
Burman, W. J., Weis, S. E., Vernon, A. A., Khan, A. Q., Benator, D., Jones, B., Silva, C. R. D. E., King, B., Lahart, C., Mangura, B. T., et al. (2007) · PubMed · Cited by 132
British HIV Association guidelines for the treatment of TB/HIV coinfection 2011
Pozniak, A., Coyne, K., Miller, R. F., Lipman, M. C. I., Freedman, A. R., Ormerod, L. P., Johnson, M., Collins, S., & Lucas, S. B. (2011) · HIV Medicine · doi:10.1111/j.1468-1293.2011.00954.x · Cited by 136
Paradoxical TB-IRIS in HIV-infected Adults: a Systematic Review and Meta-analysis
Namale, P. E., Abdullahi, L. H., Fine, S., Kamkuemah, M., Wilkinson, R. J., & Meintjes, G. (2015) · Future Microbiology · doi:10.2217/fmb.15.9 · Cited by 124
“…(2013) van Oosterhout et al. (2007) van der Plas et al. (2013) Worodria et al. (2012) Haddow et al. (2012) Bonnet et al. (2013) Naidoo et al. (2012) Lawn et al. (2007) Eshun-Wilson et al. (2010) Baalwa et al. (2008) Ali K et al. (2012) Subtotal Asia Narendran et al. (2013) Karmakar et al.…”
The Immune Reconstitution Inflammatory Syndrome in Whipple Disease
Feurle, G. E., Moos, V., Schinnerling, K., Geelhaar‐Karsch, A., Allers, K., Biagi, F., Bläker, H., Moter, A., Loddenkemper, C., Jansen, A., et al. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-11-201012070-00004 · Cited by 122
“82%), which is in the range of IRIS after treatment of tuberculosis or HIV infection (15, 16, 19).”
BackgroundHIV & immune reconstitution inflammatory syndrome (IRIS)
Sharma, S., & Soneja, M. (2011) · The Indian Journal of Medical Research · doi:10.4103/0971-5916.92632 · Cited by 151
Paradoxical reactions and immune reconstitution inflammatory syndrome in tuberculosis
Bell, L. C. K., Breen, R. A. M., Miller, R. F., Noursadeghi, M., & Lipman, M. C. I. (2015) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2014.12.030 · Cited by 121
“2% within a recent meta-analysis,(13) and considerable rates of hospitalization and intervention in TB-IRIS patients have been observed.(23,24) Similar results were reported in a large randomized controlled trial”
BackgroundResultLawn, S. D., Kranzer, K., & Wood, R. (2009) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2009.08.010 · Cited by 120
Self-citationLawn, S. D., Harries, A. D., Williams, B. G., Chaisson, R. E., Losina, E., Cock, K. M. D., & Wood, R. (2011) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.10.0483 · Cited by 119
Self-citationMarazzi, M. C., Liotta, G., Germano, P., Guidotti, G., Altan, A. M. D., Ceffa, S., Lio, M. M. S., Nielsen‐Saines, K., & Palombi, L. (2008) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2007.0217 · Cited by 115
“10 Cryptococcal meningitis has also been described as a significant cause of death in hospitalized patients in resource-limited settings.”
Haddow, L. J., Easterbrook, P. J., Mosam, A., Khanyile, N. G., Parboosing, R., Moodley, P., & Moosa, M. S. (2009) · Clinical Infectious Diseases · doi:10.1086/630208 · Cited by 114
“infection [12–22].”
The aerosol rabbit model of TB latency, reactivation and immune reconstitution inflammatory syndrome
Manabe, Y. C., Kesavan, A. K., Lopez-Molina, J., Hatem, C. L., Brooks, M. E., Fujiwara, R. T., Hochstein, K., Pitt, M. L. M., Tufariello, J. M., Chan, J., et al. (2007) · Tuberculosis · doi:10.1016/j.tube.2007.10.006 · Cited by 114
“In addition, the risk of IRIS decreases with increasing interval between the initiation of effective TB treatment and the initiation of HAART.(19) Finally, this model offers an opportunity to study the immunopathogenesis of a resistant host response to TB.”
BackgroundInfluentialVelasco, M., Castilla, V., Sanz, J., Gaspar, G., Condés, E., Barros, C., Cervero, M., Torres, R., & Guijarro, C. (2009) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31819367e7 · Cited by 112
HIV-1 tuberculosis-associated immune reconstitution inflammatory syndrome
Lai, R., Meintjes, G., & Wilkinson, R. J. (2015) · Seminars in Immunopathology · doi:10.1007/s00281-015-0532-2 · Cited by 112
Naidoo, K., Yende‐Zuma, N., Padayatchi, N., Naidoo, K., Jithoo, N., Nair, G., Bamber, S., Gengiah, S., El‐Sadr, W., FRIEDLAND, G. H., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-5-201209040-00004 · Cited by 112
“Consistent with previously published data (14, 20, 26, 28), low baseline CD4 cell count and high baseline viral load were statistically significant risk factors for IRIS in our study.”
ResultInfluentialHIV‐Associated Tuberculosis: Clinical Update
Swaminathan, S., Padmapriyadarsini, C., & Narendran, G. (2010) · Clinical Infectious Diseases · doi:10.1086/652147 · Cited by 119
“Rarely, termination of ART is required [80].”
Lahuerta, M., Ue, F., Hoffman, S., Elul, B., Kulkarni, S., Wu, Y., Nuwagaba‐Biribonwoha, H., Remien, R. H., El‐Sadr, W., & Nash, D. (2013) · Journal of Health Care for the Poor and Underserved · doi:10.1353/hpu.2013.0014 · Cited by 115
Lawn, S. D., Kranzer, K., Edwards, D., McNally, M., Bekker, L., & Wood, R. (2010) · AIDS · doi:10.1097/qad.0b013e3283390dd1 · Cited by 106
“The extraordinarily high burden of TB diagnosed during routine clinical practice in this service has been previously characterized in detail [1,4,17,21].”
BackgroundSelf-citationMortality and loss to follow-up among HAART initiators in rural South Africa
MacPherson, P., Moshabela, M., Martinson, N. A., & Pronyk, P. (2008) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/j.trstmh.2008.10.001 · Cited by 104
Meintjes, G., Rangaka, M. X., Maartens, G., Rebe, K. B., Morroni, C., Pepper, D. J., Wilkinson, K. A., & Wilkinson, R. J. (2009) · Clinical Infectious Diseases · doi:10.1086/596764 · Cited by 102
“It occurs in 8%–43% of patients who initiate cART while receiving TB treatment [4-11] and is associated with exuberant antimycobacterial immune responses [12].”
BackgroundThe Impact of the Host on Fungal Infections
Perfect, J. R. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.10.010 · Cited by 102
Narendran, G., Andrade, B. B., Porter, B. O., Chandrasekhar, C., Venkatesan, P., Menon, P. A., Subramanian, S., Selvaraj, A., Bhavani, P. K., Sekar, S., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063541 · Cited by 99
“The closer monitoring and prompt initiation of corticosteroids in cases of IRIS diagnosis might helped an early resolution of signs and symptoms of IRIS, and maybe for this reason the average duration of the IRIS events was shorter than in other studies [4,11,16].”
BackgroundResultMahnke, Y. D., Greenwald, J. H., DerSimonian, R., Roby, G. A., Antonelli, L. R. D. V., Sher, A., Roederer, M., & Sereti, I. (2012) · Blood · doi:10.1182/blood-2011-09-380840 · Cited by 96
Meintjes, G., Rabie, H., Wilkinson, R. J., & Cotton, M. F. (2009) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2009.08.013 · Cited by 92
Walensky, R. P., Wood, R., Ciaranello, A. L., Paltiel, A. D., Lorenzana, S. B., Anglaret, X., Stoler, A. W., Freedberg, K. A., & for the CEPAC-International Investigators (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000382 · Cited by 92
“[21] .”
Self-citationSwaminathan, S., & Narendran, G. (2008) · Journal of Biosciences · doi:10.1007/s12038-008-0071-2 · Cited by 92
Smith, K., Kuhn, L., Coovadia, A. H., Meyers, T., Hu, C.-C., Reitz, C., Barry, G., Strehlau, R., Sherman, G. G., & Abrams, E. J. (2009) · AIDS · doi:10.1097/qad.0b013e32832afefc · Cited by 105
“Advanced disease has been associated with IRIS in adult and pediatric populations but age has not been previously identified as a risk factor [1,3,4,6,9,11,14].”
BackgroundHaddow, L. J., Moosa, M.-Y. S., Mosam, A., Moodley, P., Parboosing, R., & Easterbrook, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040623 · Cited by 88
“Pathogen-related factors include shorter duration of anti-tuberculous or anti-cryptococcal therapy prior to ART initiation [13,16,28,29,30,31], extrapulmonary or disseminated TB [15,17,18,29], higher fungal burden in cryptococcosis [30,32], higher plasma KS-associated herpes virus (KSHV) load [22], and higher number o…”
BackgroundResultInfluentialDawson, R., Masuka, P., Edwards, D., Bateman, E. D., Bekker, L., Wood, R., & Lawn, S. D. (2010) · PubMed · Cited by 87
Self-citationCorbett, E. L., Zezai, A., Cheung, Y. B., Bandason, T., Dauya, E., Munyati, S. S., Butterworth, A. E., Rusikaniko, S., Churchyard, G., Mungofa, S., et al. (2009) · Bulletin of the World Health Organization · doi:10.2471/blt.08.055467 · Cited by 99
Providing HIV care for co-infected tuberculosis patients: a perspective from sub-Saharan Africa.
Harries, A. D., Zachariah, R., & Lawn, S. D. (2009) · PubMed · Cited by 86
Self-citationTuberculosis: From an incurable scourge to a curable disease - journey over a millennium.
Sharma, S. K., & Mohan, A. (2013) · PubMed Central · Cited by 148
Deribew, A., Taha, M., Tessema, F., Assegid, S., Duchateau, L., & Colebunders, R. (2011) · Ethiopian Journal of Health Sciences · doi:10.4314/ejhs.v21i2.69053 · Cited by 84
“A low CD4 lymphocyte count was strongly associated with the presence of active TB which is consistent with many other studies (20-22).”
ResultPathogenesis and prevention of immune reconstitution disease during antiretroviral therapy
Lawn, S. D., & Meintjes, G. (2011) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.21 · Cited by 83
Self-citationManagement of individuals requiring antiretroviral therapy and TB treatment
Cohen, K., & Meintjes, G. (2009) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e3283339309 · Cited by 81
Drug-Resistant Tuberculosis and HIV Infection: Current Perspectives
Singh, A., Prasad, R., Balasubramanian, V., & Gupta, N. (2020) · HIV/AIDS - Research and Palliative Care · doi:10.2147/hiv.s193059 · Cited by 101
“It generally presents within 3 months of the initiation of ART, and is more common with CD4 count <50 cells/cm(3).(94,95) This syndrome can present as a paradoxical worsening of the patient’s clinical status, often due to a previously subclinical and unrecognized opportunistic infection.”
BackgroundOliver, B. G., Elliott, J., Price, P., Phillips, M. R., Saphonn, V., Vun, M. C., Kaldor, J. M., Cooper, D. A., & French, M. A. (2010) · The Journal of Infectious Diseases · doi:10.1086/657082 · Cited by 80
Tuberculosis Immune Reconstitution Inflammatory Syndrome in A5221 STRIDE
Luetkemeyer, A. F., Kendall, M. A., Nyirenda, M., Wu, X., Ive, P., Benson, C. A., Andersen, J. W., Swindells, S., Sanne, I., Havlir, D. V., et al. (2013) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000030 · Cited by 78
Laureillard, D., Marcy, O., Madec, Y., Chea, S., Chan, S., Borand, L., Fernandez, M., Prak, N., Kim, C., Dim, B., et al. (2013) · AIDS · doi:10.1097/01.aids.0000432456.14099.c7 · Cited by 77
“(presumably because of a high antigen burden), low CD4þ cell count, and high viral load at ART initiation [24,40,41].”
BackgroundBiomarkers of HIV Immune Reconstitution Inflammatory Syndrome
Bonham, S., Meya, D. B., Bohjanen, P. R., & Boulware, D. R. (2008) · Biomarkers in Medicine · doi:10.2217/17520363.2.4.349 · Cited by 78
“IRIS occurs more frequently in patients who have advanced HIV/AIDS when they start ART and in those who are previously ART naïve [1,2].”
BackgroundClinical management of tuberculosis and HIV-1 co-infection
Schutz, C., Meintjes, G., Almajid, F. M., Wilkinson, R. J., & Pozniak, A. (2010) · European Respiratory Journal · doi:10.1183/09031936.00110210 · Cited by 79
“HARTUNG et al. [107] demonstrated that sputum induction performed on smear-negative patients or those unable to expectorate increased their diagnosis of TB by 29%.”
BackgroundInfluentialManzardo, C., Guardo, A. C., Letang, E., Plana, M., Gatell, J. M., & Miró, J. M. (2015) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2015.1029917 · Cited by 79
“Early initiation of cART, low CD4+ T-cell count, higher viral load, black race and extrapulmonary TB are the most common risk factors for TB-associated IRIS [18].”
BackgroundInfluentialImmune Restoration Diseases Reflect Diverse Immunopathological Mechanisms
Price, P., Murdoch, D. M., Agarwal, U., Lewin, S. R., Elliott, J., & French, M. A. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00015-09 · Cited by 72
Lawn, S. D., Kerkhoff, A. D., Vogt, M., Ghebrekristos, Y. T., Whitelaw, A. C., & Wood, R. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir1039 · Cited by 73
Self-citationMartin‐Blondel, G., Delobel, P., Blancher, A., Massip, P., Marchou, B., Liblau, R., & Mars, L. T. (2011) · Brain · doi:10.1093/brain/awq365 · Cited by 78
“Manifestations are variable, with mostly pulmonary involvement and lymphadenitis (Lawn et al., 2007).”
BackgroundInfluentialMojumdar, K., Vajpayee, M., Chauhan, N. K., & Mendiratta, S. (2010) · BMC Public Health · doi:10.1186/1471-2458-10-416 · Cited by 68
“Also, Immune Reconstitution Inflammatory Syndrome (IRIS) which is associated with low CD4 T cell counts at baseline occurs at a higher frequency in subjects with late HIV diagnosis [10].”
BackgroundSatti, H., McLaughlin, M., Hedt‐Gauthier, B., Atwood, S. S., Omotayo, D. B., Ntlamelle, L., & Seung, K. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046943 · Cited by 68
“HIV co-infection further complicates MDR-TB treatment because of the overlapping toxicities of antiretrovirals and second-line TB drugs [11], lack of knowledge about drug-drug interactions [12], and multiple potential causes of clinical deterioration during treatment [13,14].”
Lawn, S. D., Ayles, H., Egwaga, S., Williams, B. G., Mukadi, Y. D., Filho, E. D. S., Godfrey‐Faussett, P., Granich, R., & Harries, A. D. (2011) · PubMed · Cited by 67
Self-citationWorodria, W. O., Loembé, M. M., Mazakpwe, D., Luzinda, K., Menten, J., van Leth, F., Mayanja‐Kizza, H., Kestens, L., Mugerwa, R. D., Reiss, P., et al. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3182255dc2 · Cited by 65
Early mortality and cause of deaths in patients using HAART in Brazil and the United States
Grinsztejn, B. G. J., Veloso, V. G., Friedman, R. K., Moreira, R. I., Luz, P. M., Campos, D. P., Pilotto, J. H., Cardoso, S. W., Keruly, J. C., & Moore, R. D. (2009) · AIDS · doi:10.1097/qad.0b013e32832ec494 · Cited by 74
“However, though deaths attributed to immune reconstitution inflammatory syndrome have been reported, most cases appear to be selflimiting [29].”
BackgroundOptimum time to start antiretroviral therapy during HIV-associated opportunistic infections
Lawn, S. D., Török, M. E., & Wood, R. (2010) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3283420f76 · Cited by 70
“The risk of IRD is therefore higher the earlier ART is started [10, 11].”
BackgroundSelf-citationThe Clinical Impact and Cost-Effectiveness of Routine, Voluntary HIV Screening in South Africa
Walensky, R. P., Wood, R., Fofana, M. O., Martinson, N. A., Losina, E., April, M. D., Bassett, I. V., Morris, B. L., Freedberg, K. A., & Paltiel, A. D. (2010) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181fb8f24 · Cited by 65
“Patients with prevalent HIV infection have CD4 count and HIV RNA distribution parameters defined by South African cohorts (Table 1).(18,35) We estimate the proportion of HIV-infected individuals in the acute and chronic stages of disease based on published reports on the natural history of HIV-infected patients in Sou…”
BackgroundSelf-citationLate Presentation of HIV-Infected Individuals
Battegay, M., Flückiger, U. M., Hirschel, B. J., & Furrer, H. (2007) · Antiviral Therapy · doi:10.1177/135965350701200612 · Cited by 63
“However, prompt initiation of ART may be crucial in patients with very low CD4 T-cell counts to prevent AIDSrelated mortality [72].”
BackgroundTan, H. Y., Yong, Y. K., Andrade, B. B., Shankar, E. M., Ponnampalavanar, S. S. L., Omar, S. F. S., Narendran, G., Kamarulzaman, A., Swaminathan, S., Sereti, I., et al. (2015) · AIDS · doi:10.1097/qad.0000000000000557 · Cited by 63
“Risk factors for the development of an IRIS in HIVinfected patients are reported to be a low CD4þ T-cell count at ART initiation [5], robust immunological and virological response to ART [6], high antigenic burden of an underlying opportunistic infection at ART initiation [7], and early initiation of ART after opportu…”
BackgroundManagement of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art review
Lawn, S. D., Meintjes, G., McIlleron, H., Harries, A. D., & Wood, R. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-253 · Cited by 61
“Two major risk factors identified in observational studies [122-125] and in clinical trials [55,95,126] are a low CD4 count prior to ART and a shorter interval between starting TB treatment and ART.”
BackgroundSelf-citationAntiretroviral therapy of late presenters with advanced HIV disease
Battegay, M., Fehr, J. S., Flückiger, U. M., & Elzi, L. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn169 · Cited by 61
“Also, IRIS can be managed with close monitoring and symptomatic treatment including steroids.(29,30) Management of late presenters with tuberculosis is particularly challenging because of the high risk of developing IRIS, estimated at up to 32% in association with low CD4 T cell count at baseline and early ART initiat…”
BackgroundPatients presenting with AIDS in the HAART era: a collaborative cohort analysis
Mussini, C., Manzardo, C., Johnson, M. A., Monforte, A. D., Uberti‐Foppa, C., Antinori, A., Gill, M. J., Sighinolfi, L., Borghi, V., Lazzarin, A., et al. (2008) · AIDS · doi:10.1097/qad.0b013e328314b5f1 · Cited by 55
“The latter finding may reflect the real possibility of immune reconstitution disease in those patients starting HAART with untreated TB [12,13] as well as the possible effect of TB itself on the CD4 cell count [14] and also concerns about overlapping drug side effects.”
BackgroundReducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa
Lawn, S. D., Harries, A. D., Meintjes, G., Getahun, H., Havlir, D. V., & Wood, R. (2012) · AIDS · doi:10.1097/qad.0b013e3283565dd1 · Cited by 55
“The earlier ART is started and the lower the baseline CD4 cell count, the greater the risk of paradoxical TBIRD [91,92].”
BackgroundInfluentialSelf-citationLorent, N., Sebatunzi, O. R., Mukeshimana, G., den Ende, J. V., & Clerinx, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019566 · Cited by 54
“In previous reports from low-income settings the proportion of patients developing TB-associated IRIS ranged from 8–16% [11,22–25].”
BackgroundPredictive Value of Anemia for Tuberculosis in HIV-Infected Patients in Sub-Saharan Africa
Kerkhoff, A. D., Wood, R., Vogt, M., & Lawn, S. D. (2013) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000091 · Cited by 53
Self-citationHaddow, L. J., Dibben, O., Moosa, M.-Y. S., Borrow, P., & Easterbrook, P. (2011) · AIDS · doi:10.1097/qad.0b013e3283477d67 · Cited by 51
Loubière, S., Boyer, S., Protopopescu, C., Bonono, C.-R., Abega, S., Spire, B., & Moatti, J. (2009) · Health Policy · doi:10.1016/j.healthpol.2009.03.006 · Cited by 49
Immune reconstitution inflammatory syndrome
Elston, J. W. T., & Thaker, H. (2009) · International Journal of STD & AIDS · doi:10.1258/ijsa.2008.008449 · Cited by 49
d-Dimer and CRP levels are elevated prior to antiretroviral treatment in patients who develop IRIS
Porter, B. O., Ouedraogo, G. L., Hodge, J. N., Smith, M. A., Pau, A. K., Roby, G. A., Kwan, R. W., Bishop, R. J., Rehm, C. A., Mican, J. M., et al. (2010) · Clinical Immunology · doi:10.1016/j.clim.2010.02.010 · Cited by 52
Orikiiriza, J., Bakeera‐Kitaka, S., Musiime, V., Mworozi, E. A., Mugyenyi, P. N., & Boulware, D. R. (2010) · AIDS · doi:10.1097/qad.0b013e32833b260a · Cited by 48
Braitstein, P. K. A., Siika, A. M., Hogan, J. W., Kosgei, R. J., Sang, E., Sidle, J. E., Wools‐Kaloustian, K., Keter, A., Mamlin, J. J., & Kimaiyo, S. N. (2012) · Journal of the International AIDS Society · doi:10.1186/1758-2652-15-7 · Cited by 48
“Our adjusted HR ratios control for the following potential confounding variables, all measured at time of cART initiation and selected a priori based on their potential to independently affect changes in risk of mortality and/or loss to follow up: CD4 count (analyzed as a continuous variable); receipt of treatment for…”
BackgroundYotebieng, M., Rie, A. V., Moultrie, H., Cole, S. R., Adimora, A. A., Behets, F., & Meyers, T. (2010) · AIDS · doi:10.1097/qad.0b013e328339e576 · Cited by 53
“In a randomized trial of early (within 14 days) versus deferred ART initiation in adults with opportunistic infections other than TB, early ART resulted in less AIDS progression or death with no increase in adverse events including the immune reconstitution inflammatory syndrome (IRIS) [29].”
BackgroundImmune reconstitution and risk of Kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults
Jaffe, H. W., Stavola, B. L. D., Carpenter, L. M., Porter, K., & Cox, D. R. (2011) · AIDS · doi:10.1097/qad.0b013e3283489c8b · Cited by 45
“Discussion Given the known associations of Kaposi sarcoma and NHL with underlying viral infections (Kaposi sarcomaassociated herpes virus/human herpesvirus-8 for Kaposi sarcoma and Epstein–Barr virus for NHL) [18], it would not be surprising to observe these cancers occurring or worsening in the context of IRIS.”
BackgroundInfluentialPathai, S., Deshpande, A. K., Gilbert, C. E., & Lawn, S. D. (2009) · BMC Infectious Diseases · doi:10.1186/1471-2334-9-158 · Cited by 44
“This may have implications in terms of any subsequent immune reconstitution-mediated phenomena that are strongly associated with disseminated forms of TB [17].”
Self-citationAfrica, I.-S., Lawn, S. D., Campbell, L. J., Kaplan, R., Little, F., Morrow, C. D., & Wood, R. (2011) · BMC Infectious Diseases · doi:10.1186/1471-2334-11-258 · Cited by 43
“The huge burden and complications of TB in this ART service have been previously described [13-16].”
BackgroundSelf-citationThoden, J., Potthoff, A. V., Bogner, J. R., Brockmeyer, N. H., Esser, S., Grabmeier‐Pfistershammer, K., Haas, B. J., Hahn, K., Härter, G., Hartmann, M., et al. (2013) · Infection · doi:10.1007/s15010-013-0504-1 · Cited by 45
“The greatest risk factor would appear to be a low CD4 T-cell count of \50 cells/ll [12, 15].”
BackgroundConference on Retroviruses and Opportunistic Infections
Editorial Office (2007) · Southern African Journal of HIV Medicine · doi:10.4102/sajhivmed.v8i2.626 · Cited by 43
New concepts in childhood tuberculosis
Starke, J. R. (2007) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e32814b164a · Cited by 43
Metadata
- Authors
- Lawn, S. D., Myer, L., Bekker, L.-G., & Wood, R.
- Affiliations
- University of Cape Town (ZA)
- Corresponding author
- Lawn, Stephen D
- Venue
- AIDS
- Published
- 2007-01-30
- Volume
- 21
- Issue
- 3
- Pages
- 335-341
- ISSN
- 0269-9370 (ISSN-L)
- OpenAlex
- W2020198464
- Cited by
- 343
- References
- 27
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 4 · 2023: 3 · 2022: 1 · 2021: 8 · 2020: 4 · 2019: 7 · 2018: 9 · 2017: 10 · 2016: 8 · 2015: 12 · 2014: 16 · 2013: 31 · 2012: 25
- FWCI
- 51.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- AIDS (publishedVersion)
- PubMed (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (submittedVersion)
- Funders
- Wellcome Trust (074641)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- National Institute of Allergy and Infectious Diseases (1U19 AI53217-01, AI 058736-01A1, U19AI053217, R01AI058736)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Keywords
- tuberculosis, antiretroviral therapy, CD4 count, early ART initiation, risk factors, pulmonary tuberculosis, South Africa
- MeSH terms
- Adult, Antitubercular Agents, Developing Countries, Epidemiologic Methods, Female, Humans, Immune System Diseases, Inflammation, Male, South Africa, Tuberculosis, HIV Infections, AIDS-Related Opportunistic Infections, CD4 Lymphocyte Count, Anti-HIV Agents, Antiretroviral Therapy, Highly Active
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.